LLY vs MSFT: Which Is the Better Buy?
Side-by-side comparison of Eli Lilly and Company and Microsoft Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-26.
Eli Lilly and Company · Healthcare
$1,183.72
+2.1% upside to fair value
Med Conviction
Grade B
High Quality
VS
Microsoft Corporation · Technology
$497.12
+41.3% upside to fair value
High Conviction
Grade A
High Quality
QuantHub Verdict
MSFT has more upside to fair value
(+41.3%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
LLY |
MSFT |
| Current Price |
$1,183.72 |
$497.12 |
| Fair Value Estimate |
$1,208.00 |
$702.35 |
| Upside to Fair Value |
+2.1%
|
+41.3%
|
| Market Cap |
$1,114.8B |
$3,691.4B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
26.8x
|
18.3x
|
| Price / Sales |
14.0x
|
11.1x
|
| Price / FCF |
52.7x
|
55.1x
|
| Revenue Growth YoY |
+47.7%
|
+17.7%
|
| Gross Margin |
83.4%
|
67.9%
|
| Operating Margin |
49.7%
|
46.8%
|
| Return on Equity |
92.6%
|
33.2%
|
| Dividend Yield |
0.57% |
0.73% |
| FCF Yield |
1.9%
|
1.81%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
Eli Lilly is a global pharmaceutical company whose incretin franchise, led by Mounjaro and Zepbound, has become the dominant growth engine in diabetes and obesity care. The business quality is high: TTM gross margin is 83.4%, TTM operating margin is 49.7%, TTM net margin is 33.5%, and ROE is 92.6%, while revenue grew 47.7% and earnings grew 25.3% in the most recent quarter on a year-over-year bas…
Microsoft is a global infrastructure-software platform spanning Azure, Microsoft 365, security, Dynamics, Windows, GitHub and AI copilots, with high business quality supported by enterprise distribution, explicitly cited switching costs, a $678 billion commercial RPO balance, 67.9% TTM gross margin, 46.8% TTM operating margin, 40.3% TTM net margin and 33.2% ROE. Revenue grew 17.7% and earnings gr…
Accumulation Zones
| Metric |
LLY |
MSFT |
| Zone Low |
$906.00 |
$526.76 |
| Zone High |
$1,026.80 |
$597.00 |
| In Buy Zone? |
No
|
Yes
|